Blue pair of kidneys icon

In adults with type 2 diabetes and diabetic kidney disease (nephropathy) with a certain amount of protein in the urine

Lower the risks of end-stage kidney disease and hospitalization for heart failure.

Purple heart icon

In adults with established cardiovascular disease and type 2 diabetes

Lower the risks of heart attack, stroke, and cardiovascular death.

Magenta sugar cube icon

In adults with type 2 diabetes, along with diet and exercise

Significantly lower blood sugar (A1C).

INVOKANA® is the first type 2 diabetes medicine approved to lower the risks of end-stage kidney disease (ESKD), worsening of kidney function, cardiovascular death, and hospitalization for heart failure. In fact, it’s the first type 2 diabetes medicine in almost 20 years approved to treat diabetic kidney disease in people with type 2 diabetes.

In most clinical studies, INVOKANA® has helped people with type 2 diabetes reach the ADA-recommended blood sugar (A1C) goal of less than 7%.

In adults with type 2 diabetes, along with diet and exercise

Although it’s not for weight loss, INVOKANA® may help you lose weight—on average 2–3%.

Results may vary by dose and when used alone or with certain other diabetes medications. Before starting any type of exercise, please check with your doctor.

In adults with type 2 diabetes, along with diet and exercise

Although it’s not a blood pressure medication, INVOKANA® may help you see lower systolic blood pressure—on average 3–5 mmHg.

Results may vary by dose and when used alone or with metformin, sitagliptin, or insulin.

The safety and efficacy of INVOKANA® has been shown in 15 completed clinical trials with more than 20,000 patients.

The most common side effects with INVOKANA® include genital yeast infections, urinary tract infections, and changes in urination.